Neogen (NASDAQ:NEOG) Releases Earnings Results, Misses Expectations By $0.01 EPS

Neogen (NASDAQ:NEOG) announced its earnings results on Monday. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01), reports. The firm had revenue of $107.80 million during the quarter, compared to the consensus estimate of $109.93 million. Neogen had a return on equity of 9.36% and a net margin of 14.35%. The business’s revenue was up .7% compared to the same quarter last year. During the same quarter last year, the business earned $0.31 EPS.

Shares of NEOG stock opened at $65.26 on Thursday. Neogen has a 12 month low of $50.60 and a 12 month high of $79.83. The firm has a market cap of $3.45 billion, a PE ratio of 56.75, a price-to-earnings-growth ratio of 5.48 and a beta of 1.37. The stock has a 50 day moving average of $66.61 and a 200-day moving average of $66.74.

In related news, VP Jason Warren Lilly sold 2,500 shares of Neogen stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $64.61, for a total transaction of $161,525.00. Following the sale, the vice president now directly owns 12,901 shares of the company’s stock, valued at $833,533.61. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director James L. Herbert sold 30,000 shares of Neogen stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $69.64, for a total value of $2,089,200.00. The disclosure for this sale can be found here. Insiders sold 267,349 shares of company stock valued at $17,544,416 over the last three months. 1.70% of the stock is owned by company insiders.

A number of equities research analysts have issued reports on NEOG shares. BidaskClub upgraded shares of Neogen from a “sell” rating to a “hold” rating in a report on Thursday, December 5th. ValuEngine lowered Neogen from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Zacks Investment Research upgraded Neogen from a “sell” rating to a “hold” rating and set a $71.00 price objective on the stock in a research note on Wednesday, November 27th. Five equities research analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and an average target price of $74.50.

About Neogen

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.

See Also: What is the Consumer Price Index (CPI)?

Earnings History for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with's FREE daily email newsletter.